Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
about
sameAs
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaOncogenic Kras initiates leukemia in hematopoietic stem cellsRecent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemDecitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.Chronic myelomonocytic leukemia presenting as relapsing thrombotic thrombocytopenic purpura.Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Cytogenetic risk stratification in chronic myelomonocytic leukemia.Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaAchievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowAn international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic NrasSomatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsMetastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases.FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.Targeting oncogenic Ras signaling in hematologic malignancies.Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.Eosinophilia: secondary, clonal and idiopathic.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaAn International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
P2860
Q24675681-7EE8128C-B7B1-4A92-A26A-A69003AF02E4Q26768600-36F84268-6BD9-40CD-84B0-57C800D1B40AQ27331698-E2B447BA-76D3-4541-83EE-2465CF8DAFB0Q28307278-5DD06FBA-987B-492C-8759-0C70E84DA97FQ30274942-6D567AEB-791E-48D4-BA60-49DA827C800DQ30420638-DA5B60AD-0F74-4D95-A57F-6A0469E89126Q33377270-59FD5CEA-4A57-4D06-9CBB-35F8F4065AEAQ33380307-CE1D2E13-915D-464A-838B-87B8A3E12F63Q33392205-085E7522-9119-46BB-8259-42AB1607E1D6Q33406648-D675F032-7AED-4DFD-9C99-6E1F5B99803CQ33408222-321E44EF-799E-48FE-82BE-C841DD1100CDQ33583033-2FDDED2E-C641-440E-8817-EC1A42998980Q33600822-F5694942-CC24-4911-83C9-5503805711CFQ33679140-2A7930B4-E8CE-4883-9548-9F26B689C5F7Q33995610-7358F599-3F5D-448E-9377-A6E98A9C05CAQ34130332-378E54DA-7EFD-45E7-981B-A489C6914FE5Q34342071-7F499C41-9AC6-48BB-9B2D-1C8D9B27CAF6Q34393208-2D0A0451-F0FB-48B2-A2E8-F047480F1C20Q34612592-0E0FFA33-6359-4902-A3EA-FD7B68E91092Q34637945-0B16078D-ADC0-4354-A748-D79A698896B8Q34667782-3BA0536C-7E47-424A-8F4D-CEF035D1B92EQ35000581-9CDAA3EE-6A6C-4B0C-B4E0-91B2DCA7801BQ35162458-700A18D1-3B53-40AF-B2E6-817319828AC3Q35186892-A5A3A4E2-A6E4-4989-B703-4153E952D025Q35346433-F0B3728A-F841-4730-8A26-51F3C6357D72Q35654081-AEF6BEBE-0E02-4758-8B3D-965CC6B9C069Q35714782-4DFE1FA5-2198-441E-9D12-02BBE57C7D58Q35731376-C5879082-74F4-4189-ABF1-7EFD9BAD7811Q35733735-977785A5-7B30-4FFD-B04F-568526D90380Q35735401-6F7E8EF3-97B8-42D5-B256-5A2378643DA2Q35804477-9E30BEED-6670-49EE-A7C7-06A174F2B038Q36165524-20C71F0F-2374-4DCF-9B93-E06B61462C45Q36183556-5F3C9607-052D-4F95-972A-F9406838D5A0Q36352506-FFD3613B-48FF-413D-9831-EEF5E9FA5418Q36467544-9251AAC0-954D-40DC-861A-E3C817D37AC2Q36471689-7F577F77-5E58-407D-9447-DFBED40B2341Q36484688-FA3ECDF5-1D51-42DF-BF68-9A4F01F7E6DCQ36498395-FFE6AEF2-CED2-4495-969D-98EC88522209Q36708989-85BE4127-EB9E-4D50-8A51-F6540C0DD107Q36862497-B4781100-FDDD-4735-BF4D-CEF83F657A70
P2860
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
description
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Februar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: February 2002)
@en
vedecký článok (publikovaný 2002/02/01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/02/01)
@nl
наукова стаття, опублікована в лютому 2002
@uk
مقالة علمية (نشرت في فبراير 2002)
@ar
name
Prognostic factors and scoring ...... ctive analysis of 213 patients
@ast
Prognostic factors and scoring ...... ctive analysis of 213 patients
@en
Prognostic factors and scoring ...... ctive analysis of 213 patients
@nl
type
label
Prognostic factors and scoring ...... ctive analysis of 213 patients
@ast
Prognostic factors and scoring ...... ctive analysis of 213 patients
@en
Prognostic factors and scoring ...... ctive analysis of 213 patients
@nl
prefLabel
Prognostic factors and scoring ...... ctive analysis of 213 patients
@ast
Prognostic factors and scoring ...... ctive analysis of 213 patients
@en
Prognostic factors and scoring ...... ctive analysis of 213 patients
@nl
P2093
P50
P3181
P356
P1433
P1476
Prognostic factors and scoring ...... ctive analysis of 213 patients
@en
P2093
Armand B Glassman
Elihu H Estey
Francesco Onida
Miloslav Beran
Monica I Kwari
Terry L Smith
P3181
P356
10.1182/BLOOD.V99.3.840
P407
P577
2002-02-01T00:00:00Z